Benchmark Research to Open its First San Antonio Clinical Research Trial Facility, Focus on Pediatric Populations

clinical research trial facility, focus on pediatric populations

Benchmark Research, a trusted leader in the medical research field—with clinics across Texas, Louisiana, and California—is opening its first clinical trial research facility in San Antonio; its eighth site nationally. The clinic, which is located at 9480 Huebner Road near the San Antonio Medical Center, will focus on pediatric vaccine trials as well as treatments and diagnostics for common pediatric conditions. Established in 1997, Benchmark Research has developed a track record of safety and expertise, conducting more than 1,000 trials to study vaccines with over 40,000 participants including multiple COVID-19 vaccines that have been approved and are currently in distribution.

“Like the development of the COVID-19 vaccines, clinical research allows us to form a better understanding of diseases and test new treatments to detect, treat and prevent these specific illnesses. All medicine must be tested in clinical trials, and clinical trials can only be successful with the help of clinical trial participants,” Mark Lacy, chief executive officer at Benchmark Research, said. “We know that the people of San Antonio and across Bexar County will want to learn more about contributing to research that will not only impact medical treatments now but for future generations.” 

Participants in clinical research trials have access to revolutionary treatments that are not available to the public yet, have the opportunity to get their own health assessed and receive care during these appointments through blood tests and other diagnostics as part of the process that is not covered by insurance outside of their trial.

The clinic will be headed up by Olutola O. Adetona, M.D., M.P.H., who, during his career, has worked on 22 pediatric clinical research studies. Dr. Adetona has practiced in San Antonio for a dozen years and earned his medical degree from the University of Texas Health Science Center at San Antonio, where he did his residency in Pediatrics. The company has also hired site director April Valdivieso and is currently hiring for a clinical research coordinator, with other positions opening soon.

“I’m thrilled to join Benchmark Research and their momentous efforts,” Dr. Adetona said. “This facility will expand the company’s ability to analyze ‘basal metabolic rates’, which will allow us to perform pediatric studies including vaccine trials in addition to treatments and diagnostics for pediatric conditions. San Antonio is a diverse community and with children, families naturally have a lot of questions. I’m eager to help engage them in a conversation and raise awareness of the needs of partnering for clinical trials.”

Over the course of a clinical trial, participants receive compensation for their participation, which will include a specified number of visits to the facility and answering periodic phone calls regarding the study. Travel expenses will be reimbursed and all lab work is complimentary. Insurance is not required to take part in a trial.

Since 1997, Benchmark Research has investigated vaccines for H1N1 influenza during the 2009 H1N1 pandemic and Ebola virus during the 2014 Ebola virus epidemic. The company has played a role in finding successful vaccines for COVID-19 and will continue with clinical trials for additional vaccines, variants and populations as the coronavirus continues to spread throughout the United States and several parts of the world. 

Benchmark Research has been awarded by ACRP, INC Research, PharmaVoice Magazine, Pharmatimes, Pfizer, and many others and continues to receive global recognition for their quality and innovation in the field. In 2020, the company received the greatest accolades in World Vaccine Congress history and achieved the honor of being the only participant in the Vaccine Industry Excellence Awards that has ever been awarded a win or runner-up status each year. This past year, Benchmark conducted Phase 1, 2 and 3 COVID-19 studies and we have successfully enrolled over 4,000+ volunteers across our seven sites in these ongoing studies. 

For more information about Benchmark Research, visit: